---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-006210"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:01:33.167752+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeOnc secures $2.5M NIH grants for NEO212; finalizes $50M Quazar partnership

## Summary
- Awarded two NIH STTR grants totaling $2.5M to advance NEO212 in gliomas and leukemia.
- $400K Phase 1 grant supports NEO212 preclinical study in AML; $2.1M Phase 2 grant targets newly diagnosed gliomas.
- NuroMENA Holdings Ltd. incorporated by Abu Dhabi Global Market, clearing all contingencies for $50M investment from Quazar Investment.
- Partnership will fund CNS platform launch in MENA region and accelerate NEO212/NEO100 clinical programs.

## SEC filing metadata
- accession: 0001829126-25-006210
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912625006210/0001829126-25-006210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912625006210/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-006210
- JSON: https://secwatch.observer/filing/0001829126-25-006210.json
- Plain text: https://secwatch.observer/filing/0001829126-25-006210.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.